1. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
- Author
-
Parkhi M, Chatterjee D, Bal A, Vias P, Yadav BS, Prakash G, Gupta SK, and Radotra BD
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD genetics, Antigens, CD immunology, Antigens, Differentiation, Myelomonocytic genetics, Antigens, Differentiation, Myelomonocytic immunology, B7-H1 Antigen genetics, B7-H1 Antigen immunology, CD4-Positive T-Lymphocytes immunology, Central Nervous System Diseases epidemiology, Central Nervous System Diseases genetics, Central Nervous System Diseases mortality, Disease-Free Survival, Female, Humans, India epidemiology, Lymphocytes, Tumor-Infiltrating immunology, Lymphoma, Large B-Cell, Diffuse epidemiology, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse mortality, Male, Middle Aged, Prognosis, Programmed Cell Death 1 Receptor genetics, Programmed Cell Death 1 Receptor immunology, Receptors, Cell Surface genetics, Receptors, Cell Surface immunology, Central Nervous System Diseases immunology, Lymphoma, Large B-Cell, Diffuse immunology, Tumor Microenvironment
- Abstract
Primary central nervous system-diffuse large B-cell lymphoma (PCNS-DLBCL) is a rare, extranodal malignant lymphoma carrying poor prognosis. The prognostic impact of tumor microenvironment (TME) composition and the PD-1/PD-L1 immune checkpoint pathway are still undetermined in PCNS-DLBCL. We aimed to quantify the tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and PD-L1 expression in the PCNSL and evaluated their prognostic significance. All patients with histopathologically diagnosed PCNS-DLBCL over a period of 7 years were recruited. Immunohistochemistry for CD3, CD4, CD8, FOXP3, CD68, CD163, PD-1, and PD-L1 was performed on the tissue microarray. Forty-four cases of PCNS-DLBCL, who satisfied the selection criteria, were included with mean age of 55 ± 12.3 years and male-to-female ratio of 0.91:1. The mean overall survival (OS) and disease-free survival (DFS) was 531.6 days and 409.8 days, respectively. Among TILs, an increased number of CD3+ T cells showed better OS and DFS, without achieving statistical significance. CD4 positive T-cells were significantly associated with the longer OS (p = 0.037) and DFS (p = 0.023). TAMs (68CD and CD163 positive) showed an inverse relationship with OS and DFS but did not reach statistical significance (p > 0.05). Increased PD-L1 expression in immune cells, but not in tumor cells, was associated with significantly better DFS (p = 0.037). The TME plays a significant role in the prognosis of PCNS-DLBCL. Increased number of CD4+ T cells and PD-L1-expressing immune cells is associated with better prognosis in PCNS-DLBCL. Further studies with larger sample size are required to evaluate the role of targeted therapy against the TME and immune check point inhibitors in this disease., (© 2021 Scandinavian Societies for Medical Microbiology and Pathology.)
- Published
- 2022
- Full Text
- View/download PDF